MagVenture TMS Therapy System

The MagVenture TMS Therapy System is a computerized, non-invasive medical device that delivers magnetic pulses to the brain to treat Major Depressive Disorder in adolescent patients aged 15-21 years. It produces focused magnetic fields that induce electrical currents in the left dorsolateral prefrontal cortex, modulating neuronal activity as an adjunct to antidepressant therapy.

The device uses biphasic waveforms at 0.1–30 PPS frequency with a pulse width of 290 μs (±5%), delivers stimulation at 120% motor threshold intensity, and targets the left-DLPFC using a figure-of-eight air-core coil with liquid cooling. It operates through a mobile console with integrated MagPro stimulator, software interface, and head support system, offering both standard (10 Hz, 4-second trains) and iTBS (50 Hz, 2-second trains) treatment protocols.

IEC 60601-1 (general electrical safety and essential performance), IEC 60601-1-2 (electromagnetic compatibility), IEC TR 60601-4-2 (electromagnetic immunity), ISO 13485:2016 (quality management), and ISO 14971:2019 (risk management). Computational modeling using SimNIBS v4.0.1 was used to compare electric field strength between the device and predicate.

The device is substantially equivalent because it shares identical intended use, indications, anatomical targeting, and principles of operation with the predicate NeuroStar Advanced Therapy System for adolescent MDD treatment. Both use the same TMS delivery mechanism, treatment protocols (120% MT, 10 Hz standard and iTBS), and core system components. A systematic literature review covering 447 adolescent patients across five randomized trials and multiple observational studies demonstrated that TMS therapy with the MagVenture system produces clinically equivalent safety and effectiveness outcomes—with large effect sizes and no serious adverse events—comparable to the predicate device, confirming that minor design differences do not raise new safety or effectiveness questions.